Every Form 4 that MARPAI INC A (MRAI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MRAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRAI filings page.
Marpai, Inc. director Eitan Yaron reported equity compensation changes involving Class A Common Stock. On May 29, 2026, he acquired 175,000 shares at $0.00 per share as a grant or award, bringing his direct holdings to 1,224,073 shares.
A prior transaction on December 8, 2025 shows a disposition of 50,000 shares back to the issuer, described as a forfeiture of unvested restricted stock units under the award terms. The new RSUs were granted under Marpai, Inc.'s 2024 Global Stock Incentive Plan and are deemed fully vested on the issuance date, indicating compensation-related, non‑market activity.
Marpai, Inc. Chief Financial Officer Steve Andrew Johnson reported acquiring more Class A Common Stock. He made an open-market purchase of 1,100 shares at $0.62 per share and also received a grant of 125,000 restricted stock units under the company’s 2024 Global Stock Incentive Plan, which were fully vested on issuance. Following these transactions, he holds 1,024,192 shares directly, indicating a routine increase in his equity stake through both personal buying and equity compensation.
Marpai, Inc. director Shiv Sagiv reported stock-based compensation and a prior forfeiture involving Class A Common Stock. On May 29, 2026, he acquired 125,000 shares at $0.00 per share through a grant of fully vested restricted stock units under the 2024 Global Stock Incentive Plan. A prior December 8, 2025 entry shows a 50,000-share disposition to the issuer tied to the forfeiture of unvested RSUs. After these transactions, Sagiv directly holds 613,667 shares, and no derivative securities remain reported in this filing.
Marpai, Inc. director Robert M. Pons reported equity compensation and a prior forfeiture involving Class A Common Stock–linked awards. On May 29, 2026, he acquired 100,000 shares at a stated price of $0.00 per share as a grant or award. Footnotes explain these restricted stock units were granted under Marpai Inc.'s 2024 Global Stock Incentive Plan and are deemed fully vested on the issuance date. A prior transaction on December 8, 2025 shows a disposition of 50,000 shares back to the issuer, representing the forfeiture of unvested RSUs under the award terms. Following the reported transactions, Pons directly holds 484,200 shares of Class A Common Stock.
Marpai, Inc. director Jennifer Rosario Calabrese reported equity compensation changes in Class A common stock. On May 29, 2026, she acquired 100,000 shares at a stated price of $0.00 per share, reflecting a fully vested restricted stock unit award granted under Marpai Inc.'s 2024 Global Stock Incentive Plan. The filing also notes a December 8, 2025 forfeiture of 50,000 unvested RSUs returned to the issuer pursuant to the award terms. Following these transactions, she directly holds 225,000 shares of Class A common stock.
Lamendola Damien reported acquisition or exercise transactions in this Form 4 filing.
Marpai, Inc. reported that Chief Executive Officer Damien Lamendola received a grant of 300,000 shares of Class A common stock on May 29, 2026 at $0.00 per share. The shares were granted as restricted stock units under the 2024 Global Stock Incentive Plan and are deemed fully vested on the issuance date. Following the grant, he directly owns 1,650,000 Class A shares, with additional indirect holdings through entities he controls, including HillCour Investment Fund, LLC and WellEnterprises USA, LLC.
DiClaudio Colleen reported acquisition or exercise transactions in this Form 4 filing.
Marpai, Inc. director Colleen DiClaudio received 125,000 shares of Class A Common Stock as a fully vested equity award. The grant was made at a price of $0.00 per share under Marpai, Inc.'s 2024 Global Stock Incentive Plan and is deemed fully vested on the issuance date.
After this grant, DiClaudio directly holds a total of 267,500 shares of Class A Common Stock. This is a compensation-related stock award rather than an open-market purchase, so it reflects board-level equity compensation rather than a trading decision.
Marpai, Inc. director Eitan Yaron reported an open-market purchase of Class A Common Stock. On May 20, 2026, he bought 10,000 shares at a price of $0.27 per share. After this transaction, he directly holds 1,099,073 shares of Marpai stock.
SHIV SAGIV reported acquisition or exercise transactions in this Form 4 filing.
Marpai, Inc. director Shiv Sagiv received an equity grant of 100,000 shares of Class A Common Stock in the form of restricted stock units. The grant price is shown as $0.00 per share, indicating compensation rather than an open-market purchase.
According to the vesting terms, one-third of these RSUs vested on February 19, 2026, one-third vests upon execution of a Board-approved letter of intent or comparable indication of interest for a potential strategic transaction, and the final third vests upon the closing of that strategic transaction, in each case requiring continued service. After this award, Sagiv directly holds 522,000 shares of Marpai, Inc. common stock.
Marpai, Inc. (MRAI) director purchase disclosed. A director reported buying 100,000 shares of Class A common stock at $1.00 per share in a private placement on November 7, 2025, and received common warrants to purchase up to 200,000 additional shares at an exercise price of $1.00.
The warrants are exercisable immediately and remain exercisable until November 6, 2028. Following the transaction, the director directly owns 1,089,073 shares.
Marpai (MRAI) reported an insider transaction by a director. On 11/07/2025, the reporting person purchased 50,000 shares of Class A common stock at $1.00 per share and acquired common warrants for up to 100,000 shares with a $1.00 exercise price. The warrants are exercisable immediately and expire on 11/06/2028. Following the transaction, the insider beneficially owned 272,000 shares, held directly.
Marpai, Inc. (MRAI) insider transaction: Chief Operating Officer Dallas Scrip reported a private placement purchase on 11/07/2025 of 100,000 shares of Class A common stock at $1.00 per share and common warrants to purchase up to 200,000 additional shares. The warrants are exercisable immediately at $1.00 per share and remain exercisable for three years from the 11/07/2025 issuance date, expiring on 11/06/2028.
The securities are held indirectly by the Dallas S. Scrip and Michelle R. Script Trust, for which the reporting person and spouse serve as co‑trustees with shared voting and investment control.
Marpai, Inc. (MRAI) reported an insider purchase by director Robert Pons. On November 7, 2025, he bought 50,000 shares of Class A common stock in a private placement at $1.00 per share, together with common warrants to purchase up to 100,000 shares at an exercise price of $1.00.
The warrants are exercisable immediately and expire on November 6, 2028. Following the transaction, Pons beneficially owned 359,200 shares directly.